Skip to content
Buy This GLP
← Research
Evidence

Can Men With Prostate Cancer Take a GLP-1?

A matched study looked at overall mortality in men with type 2 diabetes on prostate cancer hormone therapy. Clinical trials are studying metabolic health during treatment.

Editorial profile: Neil SandersBuy This GLP Editorial Team4 min read
Deaths from any cause in one observational studyHazard ratio (95% CI)vs. DPP-4 inhibitors0.60 (0.46–0.79)vs. SGLT2 inhibitors0.76 (0.59–0.99)

Men with prostate cancer can ask their oncologist and prescriber whether a GLP-1 medicine is appropriate for a separate condition such as type 2 diabetes or obesity. The FDA labels for Ozempic and Wegovy describe these uses and do not list prostate cancer as an indication [4] [5].

What the study found during hormone therapy

Our guide to GLP-1 and SGLT2 medicines explains why different comparators matter. In the prostate cancer study, the researchers created two separate matched comparisons among men with type 2 diabetes receiving androgen deprivation therapy: 659 people per group against DPP-4 inhibitors and 1,009 per group against SGLT2 inhibitors [1].

Compared with DPP-4 inhibitors, GLP-1 users had a lower hazard of death from any cause (hazard ratio 0.60, 95% confidence interval 0.46–0.79). Major kidney events and clotting events were also less common. The analysis did not detect a significant difference in major cardiovascular events (0.87, 0.63–1.12)[1].

Compared with SGLT2 inhibitors, the hazard ratio for death from any cause was 0.76 (0.59–0.99). The study did not detect significant differences in major cardiovascular events, major kidney events or clotting events in this comparison. Some of these estimates were based on relatively few events [1].

What studies of new diagnoses found

Our guide to GLP-1 use and new cancer diagnoses covers a separate question. A Danish study compared 14,206 men who started a GLP-1 with 21,756 who started basal insulin. The main hazard ratio for a new prostate cancer diagnosis was 0.91 (95% confidence interval 0.73–1.14). The analysis of continued use of the initial treatment gave 0.80 (0.64–1.01). Both intervals included 1 [2].

What researchers are testing next

The phase II IMPACT-ADT trial is designed to compare GLP-1 medicines and dietary interventions for cardiometabolic health during androgen deprivation therapy[3].

Frequently asked

Can men with prostate cancer take a GLP-1?
Men with prostate cancer can ask their oncologist and prescriber whether a GLP-1 medicine is appropriate for a separate condition such as type 2 diabetes or obesity. The decision depends on their cancer treatment and other health needs.
Do GLP-1 medicines improve prostate cancer survival?
The study found an association with lower all-cause mortality among men with type 2 diabetes receiving hormone therapy. It did not record cause of death and cannot establish that GLP-1 use improved prostate cancer survival.
Do GLP-1 medicines prevent prostate cancer?
The evidence discussed here does not establish prevention. The primary Danish estimate comparing GLP-1 use with basal insulin was 0.91, with a confidence interval that included 1.

Sources

  1. [1] Huang SC, Cheng WY, Hou CY, Wu JY, Lai CC, Tseng WH (2026). Glucagon-like peptide-1 receptor agonist versus other anti-diabetic agents on patients with prostate cancer undergoing androgen-deprivation therapy Frontiers in Urology. PMID 42630726
  2. [2] Skriver C, Friis S, Knudsen LB, et al. (2023). Potential preventive properties of GLP-1 receptor agonists against prostate cancer: a nationwide cohort study Diabetologia. PMID 37532786
  3. [3] National Cancer Institute (2026). IMPACT-ADT Trial: Metabolic Interventions to Improve Cardiometabolic Health in Prostate Cancer Patients during Androgen Deprivation Therapy NCI Clinical Trials, NCT07202247. Source
  4. [4] Novo Nordisk (2026). Ozempic injection prescribing information, section 1 Drugs@FDA. Source
  5. [5] Novo Nordisk (2026). Wegovy prescribing information, section 1 DailyMed, U.S. National Library of Medicine. Source

Where to get it

Price the injectable sellers

The desk lists every seller that publishes an injectable figure, with the advertised price struck against the one a buyer is billed.

Open the price desk →

More in Evidence